GleamWall
中文EN

ENTX Entera Bio Ltd.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1638097 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-76.8%
TTM net income YoY-19.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-32.1%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-27,450.0%
Net margin-27,235.7%
FCF margin-17,802.4%
EBITDA margin-27,378.6%

Returns

ROE-108.0%
ROA-90.1%
ROIC (approx.)-341.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.1%
Debt / equity0.00x
Current ratio6.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-32.1%
Payout ratio—
Capex / revenue254.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$42,000$82,000
Cost of revenue$0$0$0$0$0$0$42,000$82,000
Gross profit$0$0$0$0$0$0$0$0
R&D expense$4.92M$3.20M$2.25M$1.72M$1.64M$1.52M$1.12M$1.20M
SG&A expense$157,000$124,000$128,000$54,000$118,000$103,000$123,000$96,000
Operating income-$7.26M-$4.56M-$3.54M-$3.04M-$3.26M-$2.67M-$2.56M-$2.34M
Pretax income———————-$2.34M
Income tax———————$14,000
Net income-$15.60M-$7.31M-$3.50M-$3.02M-$3.20M-$2.66M-$2.57M-$2.36M
EBITDA-$7.26M-$4.55M-$3.53M-$3.04M-$3.25M-$2.66M-$2.56M-$2.33M
EPS (basic)0.110.140.07—0.070.060.06—
EPS (diluted)0.110.140.07—0.070.060.06—
Weighted avg. shares (diluted)145.08M50.45M47.76M—47.09M46.84M43.38M—
Balance sheet
Cash & equivalents$265.88M$11.31M$4.14M$7.11M$8.57M$10.86M$12.57M$8.74M
Receivables———$0$0$0$126,000$126,000
Current assets$276.46M$18.90M$12.49M$15.30M$17.01M$19.31M$21.22M$8.97M
PP&E, net$133,000$121,000$127,000$134,000$114,000$79,000$57,000$57,000
Total assets$277.04M$19.48M$13.13M$15.99M$17.41M$19.67M$21.60M$9.39M
Current liabilities$2.15M$2.10M$1.58M$2.20M$1.57M$1.84M$1.62M$1.18M
Total liabilities$2.76M$12.21M$2.44M$2.89M$2.17M$2.41M$2.22M$1.31M
Shareholders' equity$274.28M$7.27M$10.69M$13.10M$15.23M$17.26M$19.38M$8.08M
Shares outstanding173.92M49.29M46.62M46.18M45.66M45.45M45.42M38.84M
Cash flow statement
Operating cash flow-$7.40M-$3.46M-$3.09M-$1.83M-$2.50M-$1.63M-$1.40M-$1.47M
Capital expenditure$21,000$3,000$0$27,000$43,000$29,000$8,000$3,000
Free cash flow-$7.42M-$3.47M-$3.09M-$1.86M-$2.54M-$1.66M-$1.41M-$1.47M
Investing cash flow-$21,000-$3,000$0-$27,000-$43,000-$29,000-$8,000-$3,000
Financing cash flow$261.41M$9.96M$130,000$174,000$250,000-$51,000$13.34M$3.22M
Depreciation & amortization$9,000$9,000$7,000$7,000$8,000$7,000$8,000$11,000
Stock-based compensation$1.82M$624,000$672,000$710,000$927,000$509,000$604,000$566,000

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.